Skip to main content
Clinical Trials/NCT03563768
NCT03563768
Unknown
Phase 4

Evaluation of the Strategy of "One-stop" Endovascular Treatment for Concomitant Coronary Artery Disease and Aortic Atherosclerotic Disease

Chinese Academy of Medical Sciences, Fuwai Hospital1 site in 1 country60 target enrollmentJune 30, 2018

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Enrollment
60
Locations
1
Primary Endpoint
Perioperative major bleeding (BARC≥3 grade)
Last Updated
7 years ago

Overview

Brief Summary

The study is a prospective, randomized, controlled, exploratory trail to evaluate the strategy of "one-stop" endovascular treatment for concomitant coronary artery disease and aortic atherosclerotic disease.

Detailed Description

60 patients will be allocated randomly in a 1:1 ratio into one-stop strategy group or staging strategy group. In one-stop strategy group, percutaneous coronary intervention (PCI) will be performed on the same operating room immediately after the endovascular aortic repair (EVAR); In staging strategy group, PCI will be performed several days after EVAR. The safety and effectiveness will be assessed between two groups 1 year after the operation. The economic index will be evaluated as well as.

Registry
clinicaltrials.gov
Start Date
June 30, 2018
End Date
December 31, 2020
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Responsible Party
Principal Investigator
Principal Investigator

Yi-Da Tang

Clinical professor

Chinese Academy of Medical Sciences, Fuwai Hospital

Eligibility Criteria

Inclusion Criteria

  • Aged from 18 years to 75years, male or female;
  • Aortic atherosclerotic disease with indication of EVAR;
  • Coronary heart disease with indication of PCI;
  • Provided informed consent.

Exclusion Criteria

  • Acute aortic dissection
  • Acute coronary syndrome
  • Dysfunction of coagulation system
  • Patients with gastrointestinal hemorrhage
  • Known allergy to contrasts or antiplatelet drugs
  • Renal dysfunction (GFR≤60ml/min)
  • Patient with multi-branch coronary preferred CABG

Outcomes

Primary Outcomes

Perioperative major bleeding (BARC≥3 grade)

Time Frame: 12 months

Secondary Outcomes

  • Difference of incidence of bleeding events (BARC 2 grade) between two groups(12 months)
  • Difference of incidence of all-cause death between two groups(12 months)
  • Difference of incidence of myocardial infarction between two groups(12 months)
  • Difference of operative success rate between two groups(12 months)
  • Difference of incidence of Stent thrombosis between two groups(12 months)
  • Composite of average in-patient time and average cost during hospitalization(12 months)
  • Difference of incidence of rupture of aorta between two groups(12 months)
  • Difference of incidence of pseudoaneurysm between two groups(12 months)

Study Sites (1)

Loading locations...

Similar Trials